Ardelyx Welcomes Sue Hohenleitner as New CFO for Growth
Ardelyx Announces Appointment of Sue Hohenleitner as CFO
Ardelyx, Inc. (NASDAQ: ARDX), a biopharmaceutical firm dedicated to the advancement of innovative medicines, has appointed Sue Hohenleitner as its new Chief Financial Officer (CFO). This strategic move is set to take effect on November 4, 2025, following the company's third-quarter financial reporting.
Bringing Expertise to Ardelyx
Sue Hohenleitner is not just a finance executive; she is a seasoned leader with over 30 years of experience in corporate finance, strategic planning, and operations. Previously, she held the position of Vice President and CFO at Johnson & Johnson Innovative Medicine, where she led financial strategies for a substantial $36 billion commercial business unit. Her extensive background includes driving financial performance across various therapeutic fields, making her a significant asset to Ardelyx.
Leadership Commitment
Mike Raab, President and CEO of Ardelyx, expressed enthusiasm about Hohenleitner joining the leadership team. He highlighted her visionary approach and substantial track record in executing growth strategies and operational efficiency. Raab believes her experience will play a vital role in Ardelyx's expansion plans and long-term success, ultimately delivering value to patients, employees, and shareholders.
Exciting Future Ahead
In her own words, Ms. Hohenleitner shared her excitement about joining Ardelyx at a critical juncture in its evolution. The company has already made significant strides with two first-in-class medicines aimed at addressing unmet medical needs. She looks forward to collaborating with the team to develop innovative solutions that will help patients and drive the company’s growth trajectory.
Her Track Record
Before joining Ardelyx, Hohenleitner enjoyed an impressive 28-year tenure at Johnson & Johnson. There, she spearheaded numerous finance organizations across various sectors, focusing on supply chain management, innovation, and acquisitions. Her contributions during critical strategic initiatives helped enhance operational efficiencies and fund growth opportunities. Notably, she was instrumental in acquiring two significant deals that led to successful product launches.
Professional Credentials
Ms. Hohenleitner's qualifications are impressive; she is a Certified Public Accountant (CPA) in Pennsylvania and holds a Certified Management Accountant (CMA) designation. Her academic credentials include a Bachelor of Science in Accounting from La Salle University and an MBA from Villanova University. Recently recognized as a Top 25 CFO in the biotech sector, her accolades further emphasize her standing in the industry.
About Ardelyx
Ardelyx is at the forefront of developing innovative therapies for significant unmet medical needs. With two approved commercial products in the U.S., Ardelyx is dedicated to providing essential solutions for patients. The company has established partnerships for the development and commercialization of its products in international markets, demonstrating its commitment to addressing global health challenges.
Contact Information
For more details, interested parties can reach out to Caitlin Lowie at clowie@ardelyx.com.
Frequently Asked Questions
1. Who is Sue Hohenleitner?
Sue Hohenleitner is the newly appointed Chief Financial Officer of Ardelyx, bringing over 30 years of experience in finance leadership.
2. What is Ardelyx's mission?
Ardelyx focuses on discovering, developing, and commercializing innovative medications that address unmet medical needs.
3. When does Hohenleitner officially start?
Hohenleitner will officially begin her role as CFO on November 4, 2025.
4. Where did Hohenleitner work prior to Ardelyx?
Before joining Ardelyx, Hohenleitner was the Vice President and CFO at Johnson & Johnson Innovative Medicine.
5. What are Ardelyx's current products?
Ardelyx has two commercial products in the U.S., which are focused on treating patients with specific unmet medical needs.
About The Author
Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.